Acelyrin forms scientific, patient advisory board

ACELYRIN announced the formation of a scientific and patient advisory board comprised of leading experts and advocates in thyroid eye disease, TED. This group of advisors will provide important strategic input, clinical expertise and patient perspectives as ACELYRIN prepares to advance lonigutamab, a subcutaneously delivered IgG1 monoclonal antibody targeting the anti-insulin-like growth factor 1 receptor, into Phase 3 clinical development for TED in the first quarter of 2025. Scientific Advisors: George J. Kahaly; Andrea Lora Kossler; Prem Subramanian; and Shoaib Ugradar